The mevalonate pathway which is responsible for de novo cholesterol synthesis is significantly upregulated by mutant p53, while mutant p53 depletion phenotypically reverts breast cancer cells to a more acinar-like morphology, implicating down-regulation of cholesterol synthesis as a therapeutic target for tumors bearing mutations in p53 [91]. Here, TP53 is linked to breast carcinoma.